Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

The efficacy of the inhibitors of acetylcholinesterase in Alzheimer's Disease (AD) is moderated and some patients do not respond to these treatments. Sulbutiamine potentializes cholinergic and glutamatergic transmissions, mainly in hippocampus and prefrontal cortex. This multicentric, randomized and double-blind trial evaluates the effects of the association of sulbutiamine to an anticholinesterasic drug in cognitive functions in patients with AD at an early stage (episodic memory, working memory, executive functions, attention). Patients had first donepezil (D) or sulbutiamine (S) during three months. During this period, only attention improved in both groups. During the three following months, a placebo (P) in patients D and donepezil in patients S were added. Compared to entry results, episodic memory decreased in group D + P but improved in group S + D. At the same time the improvement of attention persisted in both groups. Daylife activities only improved in group S + D. In conclusion sulbutiamine can be an adjuvant to treatment in early stage and moderate AD by anticholinesterasic drugs.

What this study adds

Evidence grade: High

This is a trial. In this small trial, patients who received sulbutiamine followed by donepezil showed improved episodic memory and daily activities compared with those who received donepezil followed by placebo. The authors conclude sulbutiamine may be an add-on to anticholinesterase treatment in early and moderate Alzheimer's disease, but this is a small study and does not show a cure.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ollat, H., Laurent, B., Bakchine, S., Michel, B. F., Touchon, J., & Dubois, B. (2007). [Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease]. L'Encephale. https://doi.org/10.1016/s0013-7006(07)91552-3

Vancouver

Ollat H, Laurent B, Bakchine S, Michel BF, Touchon J, Dubois B. [Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease]. L'Encephale. 2007. doi:10.1016/s0013-7006(07)91552-3. PMID: 17675917.

BibTeX

@article{ollat2007-17675917,
  author  = {Ollat, H. and Laurent, B. and Bakchine, S. and Michel, B. F. and Touchon, J. and Dubois, B.},
  title   = {{[Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease]}},
  journal = {L'Encephale},
  year    = {2007},
  doi     = {10.1016/s0013-7006(07)91552-3},
  pmid    = {17675917},
  url     = {https://doi.org/10.1016/s0013-7006(07)91552-3}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In this small trial, patients who received sulbutiamine followed by donepezil showed improved episodic memory and daily activities compared with those who received donepezil followed by placebo. The authors conclude sulbutiamine may be an add-on to anticholinesterase treatment in early and moderate Alzheimer's disease, but this is a small study and does not show a cure.

Study details

How this study scored 55/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 2 of 2; Times cited 3 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 55 of 100.55 of 100 points earned45 not earned

Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size and effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (L'Encephale)
Journal's citation record 0 / 4 L Encéphale: journal h-index 59 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2007 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (pubmed indexes it as a clinical or observational study)
Randomized / blinded 2 / 2 Randomized and blinded or placebo-controlled (as stated in the record)
Times cited 3 / 7 Cited 19 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.9 citations a year over 21 year(s) since 2007
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Bruno Dubois: h-index 147 (OpenAlex, whole career)
Institution's track record 2 / 3 Inserm: institution h-index 1,988 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 17675917)
Free to read 0 / 2 Behind a paywall — scores zero
Total 55 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →